OnCo

Guided routes through the map

A curated order of pages for a purpose and an audience, each step with a sentence on why it is there. Follow one end to end or jump in anywhere.

Anyone who keeps hearing about Enhertu and wants to understand why
ADCs in 30 minutes

From the idea of a guided missile to the bispecific and dual-payload ADCs now in trials, in eleven pages.

11 pages · about 30 minutes
Patients and families newly facing triple-negative breast cancer
Understand your TNBC diagnosis

What 'triple-negative' means, what the standard treatment is and why, what the tests decide, and what is coming next.

12 pages · about 40 minutes
Analysts and investors sizing up theranostics
Radiopharma for investors

The science, the approved products, the supply bottleneck, and the alpha-emitter pipeline that drives the M&A.

11 pages · about 35 minutes
Readers with no biology background
Immunotherapy from zero

How the immune system sees cancer, how tumours hide, how checkpoint inhibitors work, and where engineered immunity is heading.

11 pages · about 35 minutes
Policy makers, clinicians, and curious patients
Early detection: the blood test debate

What a multi-cancer blood test can and cannot do, the trials that will decide, and the statistics you need to judge the claims.

10 pages · about 25 minutes
Patients, caregivers, and survivors
Living well during and after treatment

The supportive-care tools with real evidence: exercise, heart protection, hair preservation, fitness assessment for older adults, and the questions to ask.

10 pages · about 25 minutes
Scientists and biotech watchers
KRAS: the forty-year target

How the most important cancer gene went from undruggable to a pan-RAS drug in pivotal trials for pancreatic cancer.

9 pages · about 30 minutes